Phase 0/I/II Cancer Prevention Clinical Trials Program Clinical Trials

Titlesort descending Intervention NCT ID Sponsor Status
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Patients With Cirrhosis Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration NCT03278925 National Cancer Institute (NCI) Recruiting
Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III... placebo, quality-of-life assessment, questionnaire administration, laboratory biomarker analysis, defined green tea catechin extract NCT00516243 National Cancer Institute (NCI) Completed
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove... defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, laboratory biomarker analysis, biopsy, mass spectrometry, high performance liquid chromatography NCT00459407 National Cancer Institute (NCI) Completed
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer diindolylmethane, placebo, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study NCT00450229 National Cancer Institute (NCI) Completed
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection DNA Plasmid Encoding Interleukin-12 INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment NCT02772003 National Cancer Institute (NCI) Recruiting
Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers Laboratory Biomarker Analysis, Placebo, Questionnaire Administration, Dolcanatide NCT03300570 National Cancer Institute (NCI) Active, not recruiting
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment NCT02273362 National Cancer Institute (NCI) Recruiting
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous... Erlotinib Hydrochloride, Laboratory Biomarker Analysis NCT02961374 National Cancer Institute (NCI) Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma erlotinib hydrochloride, placebo, laboratory biomarker analysis NCT00754494 National Cancer Institute (NCI) Completed
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With... acetylsalicylic acid, esomeprazole magnesium, placebo NCT00474903 National Cancer Institute (NCI) Completed

Pages